FTSE 100 news / Companies and sectors / GSK / ViiV's Cabenuva meets primary endpoint in unsuppressed HIV trial
ViiV's Cabenuva meets primary endpoint in unsuppressed HIV trial
+6.6 strongly positive
ViiV's long-acting Cabenuva met its primary endpoint of superior viral suppression versus daily oral therapy.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| AD HOC NEWS | 2 | +2.5 |
| BioSpace | 1 | +10.0 |
| Indian Pharma Post | 1 | +10.0 |
| Seeking Alpha | 1 | +9.3 |
| FirstWord Pharma | 1 | +9.2 |
| London South East | 1 | +7.5 |
| Yahoo Finance | 1 | +4.2 |
| Fierce Pharma | 1 | +3.7 |
Day by day
Friday 9 October 2026
ViiV's long-acting HIV treatment met its Phase IIIb endpoint.
- +10.0 GSK’s ViiV says long-acting HIV treatment meets key Phase IIIb endpoint
ViiV long-acting HIV treatment meets Phase IIIb endpoint - +1.7 GSK reported Cabenuva trial success. GSK stock trades 1.38 percent below its prior close.
Cabenuva trial success but shares slightly lower
Thursday 8 October 2026
Coverage of ViiV's CROWN trial endpoint continues.
- +4.2 GSK (LSE:GSK) Stock May Trade Below Fair Value Despite Fresh Cabenuva Trial News
Fresh Cabenuva trial news; possibly trading below fair value. - +3.3 GSK’s ViiV Healthcare reports CROWN endpoint: GSK stock pre-market at EUR 20.86, minus 0.62 percen
ViiV trial endpoint reported; share price slightly lower pre-market.
Wednesday 7 October 2026
ViiV's long-acting Cabenuva met its primary endpoint of superior viral suppression versus daily oral therapy.
- +10.0 ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
ViiV Cabenuva trial meets primary endpoint of superior viral suppression - +9.3 GSK-owned ViiV succeeds in late-stage trial for HIV therapy
ViiV succeeds in late-stage HIV trial - +9.2 GSK's long-acting Cabenuva scores win in unsuppressed HIV
Positive Cabenuva trial win in unsuppressed HIV - +7.5 GSK celebrates "important insights" from Cabenuva study
GSK welcomes insights from Cabenuva study - +3.7 ViiV girds data package for Cabenuva in competitive HIV treatment market
ViiV builds data package in competitive market; modestly positive